Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD
- PMID: 2995573
- DOI: 10.1002/jmv.1890170103
Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD
Abstract
Groups of 5-week-old BALB/c mice were immunized intraperitoneally with approximately 10 micrograms of purified alum-precipitated glycoprotein gB or gD of either herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) origin. Control mice received injections of alum-precipitated 1% bovine serum albumin (BSA). Following a second immunization 4 weeks later, seroconversion was confirmed by demonstrating the presence of glycoprotein-specific antibody by immune precipitation. All animals were challenged with lethal doses of either HSV-1 or HSV-2 by footpad inoculation and assessed for acute virus-induced neurological disease and the development of ganglionic latency. Whereas 70% of control (BSA-immunized) HSV-1-infected animals developed ascending myelitis and died, 100% of mice immunized with either gB-1, gB-2, gD-1, or gD-2 antigens remained free of clinical illness and survived HSV-1 challenge. In contrast, gB-1-or gB-2-immunized mice were not protected against acute HSV-2-induced neurological disease and showed a mortality rate of 60-90% (equivalent to that seen in controls), although mean survival times were prolonged. However, significant protection against HSV-2 challenge was observed with gD-1 or gD-2 immunization. When sacral ganglia were removed from surviving mice 9-12 months after virus challenge, latent virus was detected in all gB- or gD-immunized animals, although the extent of latent infection was restricted. These results provide evidence that glycoprotein gD might be superior to glycoprotein gB as an immunogen for the control of acute HSV-1 and HSV-2 neurological disease in mice. However, neither glycoprotein prevents ganglionic latency, the source of virus for recurrent herpesvirus infections.
Similar articles
-
Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.J Exp Med. 1985 Oct 1;162(4):1304-18. doi: 10.1084/jem.162.4.1304. J Exp Med. 1985. PMID: 2995536 Free PMC article.
-
Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.Infect Immun. 1981 Oct;34(1):192-9. doi: 10.1128/iai.34.1.192-199.1981. Infect Immun. 1981. PMID: 6271681 Free PMC article.
-
Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.J Virol. 1988 May;62(5):1530-4. doi: 10.1128/JVI.62.5.1530-1534.1988. J Virol. 1988. PMID: 2833606 Free PMC article.
-
Live vaccinia virus recombinants expressing herpes simplex virus genes.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S898-903. doi: 10.1093/clind/13.supplement_11.s898. Rev Infect Dis. 1991. PMID: 1664124 Review.
-
Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S924-34. doi: 10.1093/clind/13.supplement_11.s924. Rev Infect Dis. 1991. PMID: 1664130 Review.
Cited by
-
Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.Clin Vaccine Immunol. 2011 Oct;18(10):1702-9. doi: 10.1128/CVI.05071-11. Epub 2011 Aug 18. Clin Vaccine Immunol. 2011. PMID: 21852545 Free PMC article.
-
Expression of cell-associated and secreted forms of herpes simplex virus type 1 glycoprotein gB in mammalian cells.J Virol. 1987 Feb;61(2):315-25. doi: 10.1128/JVI.61.2.315-325.1987. J Virol. 1987. PMID: 3027363 Free PMC article.
-
Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines.J Clin Microbiol. 1990 Jan;28(1):11-5. doi: 10.1128/jcm.28.1.11-15.1990. J Clin Microbiol. 1990. PMID: 2153698 Free PMC article.
-
Deletion of the carboxy-terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B does not affect oligomerization, heparin-binding activity, or its ability to protect against HSV challenge.Arch Virol. 1996;141(6):1153-65. doi: 10.1007/BF01718618. Arch Virol. 1996. PMID: 8712932
-
Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.J Virol. 1989 Jul;63(7):2951-8. doi: 10.1128/JVI.63.7.2951-2958.1989. J Virol. 1989. PMID: 2542605 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical